Drug-induced thrombocytopenia in critically ill patients

Critical Care Medicine

Volumn 38, Issue 6 SUPPL., 2010, Pages

  Priziola, Jennifer L ^a   Smythe, Maureen A ^b,c   Dager, William E ^d,e  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c Beaumont Hospital Royal   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Critical care; Critically ill; Drug induced thrombocytopenia; Intensive care unit; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ALCOHOL; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ARGATROBAN; CINCHONA ALKALOID; CORTICOSTEROID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GOLD SALT; HEPARIN; HIRULOG; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; LEPIRUDIN; LINEZOLID; LOW MOLECULAR WEIGHT HEPARIN; PENICILLIN G; QUINIDINE; QUININE; RIFAMPICIN; SEDATIVE AGENT; SULFAMETHOXAZOLE; TIROFIBAN; UNINDEXED DRUG; VANCOMYCIN;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNE MEDIATED INJURY; INCIDENCE; INTENSIVE CARE UNIT; LUNG TUBERCULOSIS; MEDICAL DOCUMENTATION; PATIENT MONITORING; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 77953037881     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181de0b88     Document Type: Article

References (92)

1. Moreau D, Timsit JF, Aurelien VM, et al: Platelet count decline, an early prognostic marker in critically ill patients with prolonged ICU stays. Chest 2007; 131: 1735-1741
2. Vanderschueren S, De Weerdt A, Malbrain M, et al: Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000; 28: 1871-1876
3. Crowther MA, Cook DJ, Meade MO, et al: Thrombocytopenia in medical-surgical critically ill patients: Prevalence, incidence and risk factors. J Crit Care 2005; 20:348-353
4. George JN, Raskbo GE, Shah SR, et al: Druginduced thrombocytopenia: A systematic review of published case reports. Ann Intern Med 1998; 129:886-890
5. Aster RH, Curtis BR, McFarland JG, et al: Drug-induced immune thrombocytopenia: Pathogenesis, diagnosis and management. J Thromb Haemost 2009; 7:911-918
6. Aster RH, Boughie DW: Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357:580-587
7. Kenney B, Stack G: Drug-induced thrombocytopenia. Arch Pathol Lab Med 2009; 133: 309-314
8. Visentin GP, Liu CY: Drug-induced thrombocytopenias. Hematol Oncol Clin North Am 2007; 21:685-696
9. Wazny L, Ariano RE: Evaluation and management of drug induced thrombocytopenia in the acutely ill patient. Pharmaoctherapy 2000; 20:292-307
10. Andres E, Dali-Youcef N, Serraj K, et al: Recognition and management of drug induced cytopenias: The example of idiosyncratic drug-induced thrombocytopenia. Exp Opin Drug Saf 2009; 8:183-190
11. Drews RE: Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med 2003; 24: 607-622
12. Warkentin TE: Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2007; 21:589-607
13. Napolitano LM, Warkentin TE, AlMahameed A, et al: Heparin-induced thrombocytopenia in the critical care setting: Diagnosis and management. Crit Care Med 2006; 34: 2898-2911
14. Selleng K, Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007; 35: 1165-1176
15. Warkentin TE, Greinacher AG: Heparin induced thrombocytopenia and Cardiovascular Surgery. Ann Thorac Surg 2003; 76:2121-31
16. Verma AK, Levine M, Shalansky SJ, et al: Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003; 23:745-753
17. Gettings EM, Brush KA, Van Cott EM, et al: Outcome of postoperative critically ill patients with heparin-induced thrombocytopenia: An observational retrospective casecontrol study. Crit Care 2006; 10:R161
18. Schenk S, El-Banayosy A, Prohaska W, et al: Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support. J Thorac Cardiovasc Surg 2006; 131: 1373-1381
19. Koster A, Huebler S, Potapov E, et al: Impact of heparin-induced thrombocytopenia on outcome in patients with ventricular assist device support: Single-institution experience in 358 consecutive patients. Ann Thorac Surg 2007; 83:72-76
20. Warkentin TE, Greinacher A, Koster A, et al: Treatment and prevention of heparininduced thrombocytopenia; American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008; 133:340s-380s
21. Crespo EM, Oliveira GBF, Honeycutt EF, et al: Evaluation and management of thrombocytopenia and suspected heparin induced thrombocytopenia in hospitalized patients: The complications after thrombocytopenia caused by heparin (CATCH) registry. Am Heart J 2009; 157:651-657
22. Smythe MA, Koerber JM, Forsyth L, et al: Argatroban dosage requirements and outcomes in intensive care versus nonintensive care patients. Pharmacotherapy 2009; 29: 1073-1081
23. Dager WE: Dosing nomograms: Silos on a slope. Ann Pharmacother 2009; 43:114-117
24. Aster RH: Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005; 127:53S-59S
25. ReoPro (abciximab): Prescribing information. Leiden, The Netherlands, Centocor BV, 2005
26. AGGRESTAT (tirofiban hydrochloride): Prescribing information. Somerset, NJ, Medicure International, 2008
27. Integrilin (eptifibatide): Prescribing information. Kenilworth, NJ, Schering Corporation, 2009
28. Russell KN, Schnabel JG, Rochetto RP, et al: Acute profound thrombocytopenia associated with readministration of eptifibatide. Case report and review of the literature. Pharmacotherapy 2009; 29:867-874
29. Refaat M, Smith AJC, Edmundowicz D: Eptifibatide-induced thrombocytopenia. J Thromb Thrombolysis 2008; 25:204-206
30. Dorsh MP, Montague D, Rodgers JE, et al: Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia. Pharmacotherapy 2006; 26: 423-427
31. Dery JP, Braden GA, Lincoff AM, et al: Final results of the ReoPro readministration registry. Am J Cardiol 2004; 15:979-984
32. Aster RH, Curtis BR, Bougie DW: Thrombocytopenia resulting from sensitivity to GPIIbIIIa inhibitors. Semin Thromb Hemost 2004; 30:569-577
33. Aster RH, Curtis BR, Bougie DW, et al: Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost 2006; 4:678-679
34. Said SM, Hahn J, Schleyer E, et al: Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia. Clin Res Cardiol 2007; 96: 61-69
35. Huxtable LM, Tafreshi MJ, Rakkar ANS: Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006; 97: 426-429
36. Bougie DW, Wilker PR, Wuitschick ED, et al.: Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligandoccupied GPIIb/IIIa. Blood 2002; 100: 2071-2076
37. Llevadot J, Coulter SA, Giugliano TP. A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis 2009; 9:175-180
38. Epelman S, Nair D, Downey R, et al: Eptifibatide-induced thrombocytopenia and thrombosis. J Thromb Thrombolysis 2006; 22:151-154
39. Dunkley S, Evans S, Gaudry L, et al: Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events. Platelets 2005; 16:462-468
40. Gore JM, Spencer FA, Gurkinkel EP, et al: TCY in patients with acute coronary syndrome (from the global registry of acute coronary events [GRACE]). Am J Cardiol 2009; 103:175-180
41. Shantsila E, Lip GYH, Chong BH: Heparin induced TCY. A contemporary clinical approach to diagnosis and management. Chest 2009; 135:1651-1664
42. Granowitz EV, Brown RB: Antibiotic adverse reactions and drug interactions. Crit Care Clin 2008; 24:421-442
43. Yang CJ, Chen TC, Wang CS: Should we stop the effective antibiotics immediately when treating severe sepsis in patients with antibiotic-related thrombocytopenia? J Infect 2009; 58:389-393
44. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension prior to initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596
45. Gerson SL, Kaplan SL, Bruss JB, et al: Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 2002; 46:2723-2726
46. Bernstein WB, Trotta RF, Rector JT, et al: Mechanisms of linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 2003; 37:517-520
47. Zyvoxx (linezolid): Prescribing information. New York, NY, Pfizer, 2008
48. Birmingham MC, Rayner CR, Meagher AK, et al: Linezolid for the treatment of multidrug resistant, gram-positive infections: Experience from a compassionate-use program. Clin Infect Dis 2003; 36:159-168
49. Attassi K, Hershberger E, Alam R, et al: Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34:695-698
50. Rao N, Ziran BH, Wagener MM, et al: Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis 2004; 38: 1058-1064
51. Grim SA, Rene L, Gupta S, et al: Safety of linezolid in patients with baseline thrombocytopenia. J Antimicrob Chemother 2008; 62:850-851
52. Grau S, Morales-Molina A, Mateu-de Antonio J, et al: Linezolid: Low pre-treatment platelet values could increase the risk of thrombocytopenia. J Antimicrob Chemother 2005; 56: 440-441
53. Matsumoto K, Takeda Y, Takeshita A, et al: Renal function as a predictor of linezolidinduced thrombocytopenia. Int J Antimicrob Agents 2009; 33:98-99
54. Brier ME, Stalker DJ, Aronoff GR, et al: Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47:2775-2780
55. Lin YH, Wu VC, Tsai IJ, et al: High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 2006; 28:345-351
56. Wu VC, Wang YT, Wang CY, et al: High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42:66-72
57. Plachouras D, Giannitsioti E, Anhanassia S, et al: No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis 2006; 43: 89-91
58. Soriano A, Ortega M, Garcia, et al: Comparative study of the effects of pyridoxine, rifampin and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother 2007; 51: 2559-2563
59. Spellberg B, Yoo T, Bayer AS: Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 2004; 54:832-835
60. Kenney B, Tormer CA: Acute Vancomycindependent immune thrombocytopenia as an anamnestic response. Platelets 2008; 19: 379-383
61. Marraffa J, Guharoy R, Duggan D, et al: Vancomycin-induced thrombocytopenia: A case proven with rechallenge. Pharmacotherapy 2003; 23:195-198
62. Von Drygalski A, Curtis BR, Bougie DW, et al: Vancomycin-induced immune mediated thrombocytopenia. N Engl J Med 2007; 356: 904-910
63. Howard CE, Adams La, Admire JL, et al: Vancomycin-induced thrombocytopenia: A challenge and rechallenge. Ann Pharmacother 1997; 31:315-318
64. Fletcher C, Pearson C, Choi SC, et al: In vitro comparison of antiplatelet effects of betalactam penicillins. J Lab Clin Med 1986; 108: 217-223
65. Fass RJ, Copelan EA, Brandt JT, et al: Platelet-mediated bleeding caused by broadspectrum penicillins. J Infect Dis 1987; 155: 1242-1247
66. ten Berg MJ, Huisman A, Souverein PC, et al: Drug-induced thrombocytopenia: A population study. Drug Saf 2006; 29:713-721
67. Wright AJ: The penicillins. Mayo Clin Proc 1999; 74:290-307
68. Perez-Vazquez A, Pastor JM, Riancho JA: Immune thrombocytopenia caused by pipercillin/tazobactam. Clin Infect Dis 1998; 27: 650-651
69. Warkentin TE: Thrombocytopenia due to platelet destruction and hypersplenism. In: Hematology: Basic Principles and Practice. Fifth Edition. Hoffman R, Benz EJ Jr, Shattil SJ, et al (Eds.). Philadelphia, Churchill Lippincott, 2008, pp 2121-2125
70. Papaioannides D, Bouropoulos C, Korantzopoulos: Co-trimazole induced acute thrombocytopenic purpura. Emerg Med J 2003; 20:E3
71. Pedersen-Bjergaard U, Andersen M, Hansen PB: Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol 1998; 54:701-706
72. Yamreudeewong W, Fosnocht BJ, Weixeiman JM: Severe thrombocytopenia possible associated with TMP/SMX therapy. Ann Pharmacother 2002; 36:78-82
73. Pereira J, Hidalgo P, Ocqueteau M, et al: Glycoprotein Ib/IX complex is the target of rifampicin-induced immune thrombocytopenia. Br J Haematol 2000; 110:907-910
74. Munoz ME, Ruiz P, Borobia AM, et al: Rifampin related acute renal failure, thrombocytopenia, and leukocytoclastic vasculitis. Ann Pharmacother 2008; 42:727-728
75. Cheah CY, De Keulenaer B, Leahy MF: Fluoroquinolone-induced immune thrombocytopenia: a report. Intern Med J 2009; 39: 619-623
76. Cipro (ciprofloxacin hydrochloride): Prescribing information. Wayne, NJ, Bayer Healthcare Pharmaceuticals, 2008
77. Levaquin (levofloxacin): Prescribing information. Gurabo, Puerto Rico, Janssen Ortho, 2009
78. Avelox (moxifloxacin hydrochloride): Prescribing information. Wayne, NJ, Bayer Healthcare Pharmaceuticals, 2008
79. 2 Antagonist-induced thrombocytopenia: Is this a real phenomenon? Intensive Care Med 2002; 28:459-465
80. Ecker RD, Wijdicks EFM, Wix K, et al: Does famotidine induce thrombocytopenia in neurosurgical patients? J Neurosurg Anesthesiol 2004; 16:291-293
81. Gentilini G, Curtis BR, Aster RH: An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for druginduced antibodies. Blood 1998; 98: 2359-2365
82. Shaley O, Seror D: Cimetidine and ranitidine may not cross-react to cause thrombocytopenia. J Intern Med 1991; 230:87-88
83. Gafter U, Zevin D, Komlos L, et al: Thrombocytopenia associated with hypersensitivity to ranitidine: Possible cross-reactivity with cimetidine. Am J Gastroenterol 1989; 84: 560-562
84. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hemat Oncol 2000; 22:62-65
85. De Berardis D, Campanella D, Matera V, et al: Thrombocytopenia during valproic acid treatment in young patients with new onset bipolar disorder. J Clin Psychopharmacol 2003; 23: 451-458
86. Holtzer CD, Reisner-Keller LA: Phenytoininduced thrombocytopenia. Ann Pharmacother 1997; 31:435-436
87. Thorning G, Raghaven K: Fatal phenytoininduced thrombocytopenia in a neurosurgical patient. Eur J Anaesthiol 2007; 24:889-901
88. Salzman MB, Smith EM: Phenytoin-induced thrombocytopenia treated with intravenous immune globulin. J Pediatr Hematol Oncol 1998; 20:152-153
89. Weinberger I, Rotenberg Z, Fuchs J, et al: Amiodarone-induced thrombocytopenia. Arch Intern Med 1987; 147:735736
90. Landrum EM, Siegert EA, Hanlon JT, et al: Prolonged thrombocytopenia associated with procainamide in an elderly patient. Ann Pharmacother 1994; 28:11721176
91. Meisner DJ, Carlson RJ, Gottlieb AJ: Thrombocytopenia following sustained release procainamide. Arch Intern Med 1985; 145:700-702
92. Cimo PL, Pisciotta AV, Desai RG, et al: Detection of drug-dependent antibodies by the 51Cr platelet lysis test: Documentation of immune thrombocytopenia induced by diphenlhydantoin, diazepam, and sulfisoxazole. Am J Hematol 1977; 2:65-72